Cancer cells mount an instant, energy‑rich response to being physically squeezed, according to a study published in the journal Nature Communications. The surge of energy is the first reported instance of a defensive mechanism that helps cells repair D…
A new discovery made by researchers from The Australian National University (ANU) could lead to smarter, more effective treatments for Hodgkin lymphoma, a common blood cancer.
Weill Cornell Medicine researchers have discovered that PD-1—a molecule best known for putting the brakes on immune cells—also plays a critical role in helping T cells become long-term immune defenders in the skin. Early during infection, PD-1 acts lik…
Of the 3.6 million babies born in the United States each year, about 80% begin breastfeeding in their first month of life. Breastfeeding has known benefits for both mother and child, reducing maternal risk of breast and ovarian cancers, type 2 diabetes…
Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment—immunotherapy—may help change the environment where cancer cells live, possibly helping the immune system respond more effe…
New designer proteins created using an AI tool can selectively target peptide segments that bind to markers on diseased cancer cells, acting like molecular flags that signal immune cells to attack and destroy the threats.
A team headed by Claude Perreault, Director of IRIC’s Immunobiology Research Unit and Professor at the Faculty of Medicine at Université de Montréal, has identified novel tumor antigens that could lead to the development of vaccines for the treatment o…
Head and neck squamous cell carcinomas (HNSCC) are a group of cancers that affect cells in and around our mouth and nose. With 890,000 new cases and 450,000 deaths annually, HNSCC accounts for roughly 4.5% of cancer diagnoses and deaths worldwide.
UCSF researchers have found that certain antiviral genes become less active over time in lupus, revealing why some patients see their symptoms fade as they age.
The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical study led by researchers at Sylvester Comprehensive Cancer…
